Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients
Status:
Unknown status
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This is a phase III, multicenter, randomized, double-blind, placebo-controlled study planning
to include approximately 387 T2DM patients who have received at least 8 weeks of treatment
with diet control and exercise； have not received any glucose-lowering agents within the 8
weeks prior to screening; and have inadequately controlled blood glucose.The subjects would
receive PEX168 or placebo monotherapy for 52weeks in total.